Analysis of a new H2 receptor antagonist, 3-amino-5-[3-[4-(1-piperidinoindanyloxy)]propylamino]-1-methyl-1 H-1,2,4-triazole, in human plasma and urine by high-performance liquid chromatography.
A high-performance liquid chromatographic (HPLC) method for the determination of a new H2 receptor antagonist, 3-amino-5-[3-[4-(piperidinoindanyloxy)]propylamino] -1-methyl-1H-1,2,4-triazole (I), in human plasma and urine was developed. The method employs liquid-liquid extraction of the analyte and an internal standard and chromatographic separation using an alkylphenyl-bonded HPLC column. The total time of chromatography was less than 10 min. Sensitivity was 10 ng/ml for the plasma analysis and 1 microgram/ml for the analysis of I from urine. The coefficients of variation, based on interpolated concentrations, were less than 10%. The method was used for more than 5000 samples during clinical pharmacokinetic studies.
D000284:Administration, Oral; D002851:Chromatography, High Pressure Liquid; D006635:Histamine H2 Antagonists / Q000032:analysis* / Q000097:blood / Q000652:urine; D006801:Humans; D007192:Indenes / Q000032:analysis* / Q000097:blood / Q000652:urine; D007202:Indicators and Reagents; D007262:Infusions, Intravenous; D014230:Triazoles / Q000032:analysis* / Q000097:blood / Q000652:urine
D006635:Histamine H2 Antagonists; D007192:Indenes; D007202:Indicators and Reagents; D014230:Triazoles; C057317:RGW 2568